Stock tanked last year because hep b trials killed a chimp, so they shelved project to focus on Amgen and RNAi program therapies.
Buy half now, buy the other half on a pullback. Fucking beautiful chart. BEAUTIFUL
Only short to medium term risk is dilution, which is a very real possibility . The buying is just SO strong though, wow. BEAUTIFUL, like, it's ....just,.....its a beautiful chart. So firm and consistent, and green, with heavy volume. For it to have responded so strongly after a major investor left is very indicative of positive outcomes in the future.
Late 2016
-Amgen to Receive Worldwide Exclusive License to Arrowhead's RNAi ARC-LPA Program
-Amgen Receives Exclusive License Option to RNAi Therapy for Undisclosed Cardiovascular Target
-Arrowhead to Receive $56.5 Million in Upfront Payments and Initial Equity Investment and up to an Additional $617 Million in ------Potential Milestone and Equity Payments
up to $617 million in option payments, and development, regulatory and sales milestone payments
"Arrowhead's expertise in RNAi makes them a valuable partner as we translate genetic discoveries into potential therapies that can improve health outcomes for patients," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "This collaboration builds upon our commitment to cardiovascular disease with targets that we believe are uniquely suited for RNAi-based therapy."
"We have made great advances to our proprietary subcutaneous RNAi delivery vehicle and in RNAi trigger modification and stabilization that enable rapid development of new RNAi therapeutics across multiple disease areas," said Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead. "Our capabilities and platform technologies are becoming increasingly validated, so we feel that now is a great time to expand the reach of our technologies and partner with other companies to maximize the value of our assets. We are thrilled to be working with Amgen, one of the world's leading biotechnology companies, on this collaboration. Amgen's extensive development, regulatory, and commercial expertise makes them an ideal partner, and we look forward to a long and productive relationship."
Buy half now, buy the other half on a pullback. Fucking beautiful chart. BEAUTIFUL
Only short to medium term risk is dilution, which is a very real possibility . The buying is just SO strong though, wow. BEAUTIFUL, like, it's ....just,.....its a beautiful chart. So firm and consistent, and green, with heavy volume. For it to have responded so strongly after a major investor left is very indicative of positive outcomes in the future.
Late 2016
-Amgen to Receive Worldwide Exclusive License to Arrowhead's RNAi ARC-LPA Program
-Amgen Receives Exclusive License Option to RNAi Therapy for Undisclosed Cardiovascular Target
-Arrowhead to Receive $56.5 Million in Upfront Payments and Initial Equity Investment and up to an Additional $617 Million in ------Potential Milestone and Equity Payments
up to $617 million in option payments, and development, regulatory and sales milestone payments
"Arrowhead's expertise in RNAi makes them a valuable partner as we translate genetic discoveries into potential therapies that can improve health outcomes for patients," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "This collaboration builds upon our commitment to cardiovascular disease with targets that we believe are uniquely suited for RNAi-based therapy."
"We have made great advances to our proprietary subcutaneous RNAi delivery vehicle and in RNAi trigger modification and stabilization that enable rapid development of new RNAi therapeutics across multiple disease areas," said Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead. "Our capabilities and platform technologies are becoming increasingly validated, so we feel that now is a great time to expand the reach of our technologies and partner with other companies to maximize the value of our assets. We are thrilled to be working with Amgen, one of the world's leading biotechnology companies, on this collaboration. Amgen's extensive development, regulatory, and commercial expertise makes them an ideal partner, and we look forward to a long and productive relationship."
註釋
Changed mind, waiting for pull back, no buy half. Everytime I chase, I lose, don't care how nice this chart looks. Doesn't have any significant catalyst yet
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。